BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gao SJ, Guo H, Luo G. Omicron variant (B.1.1.529) of SARS-CoV-2, a global urgent public health alert! J Med Virol 2021. [PMID: 34850421 DOI: 10.1002/jmv.27491] [Cited by in Crossref: 77] [Cited by in F6Publishing: 89] [Article Influence: 38.5] [Reference Citation Analysis]
Number Citing Articles
1 Guo L, Zhao P, Jia Y, Li T, Huang L, Wang Z, Liu D, Hou Z, Zhao Y, Zhang L, Li H, Kong Y, Li J, Wang X, Rong M. Efficient inactivation of the contamination with pathogenic microorganisms by a combination of water spray and plasma-activated air. J Hazard Mater 2023;446:130686. [PMID: 36610342 DOI: 10.1016/j.jhazmat.2022.130686] [Reference Citation Analysis]
2 Wang M, Mi H, Li N, Shi Q, Sun W, He T, Lin J, Jin W, Gao X, Hu B, Su C, Pan J. Association between the overall burden of comorbidity and Ct values among the older patients with Omicron infection: Mediated by inflammation. Front Immunol 2023;14. [DOI: 10.3389/fimmu.2023.1145044] [Reference Citation Analysis]
3 Yan J, Wang J, Ding L, Liu S, Zhan Y, Lu J, Li Z, Gu L, Li P, Zhu M, Gao Y, Gong X, Ban H, Cai H, Mou S. Adaptive immune dysfunction in patients with COVID-19 and impaired kidney function during the omicron surge. Clin Immunol 2023;248:109271. [PMID: 36806705 DOI: 10.1016/j.clim.2023.109271] [Reference Citation Analysis]
4 Wang X, Li J, Liu H, Hu X, Lin Z, Xiong N. SARS-CoV-2 versus Influenza A Virus: Characteristics and Co-Treatments. Microorganisms 2023;11:580. [DOI: 10.3390/microorganisms11030580] [Reference Citation Analysis]
5 Gao X, Xia Y, Liu X, Xu Y, Lu P, Dong Z, Liu J, Liang G. A perspective on SARS-CoV-2 virus-like particles vaccines. Int Immunopharmacol 2023;115:109650. [PMID: 36649673 DOI: 10.1016/j.intimp.2022.109650] [Reference Citation Analysis]
6 Oke SI, Ekum MI, Akintande OJ, Adeniyi MO, Adekiya TA, Achadu OJ, Matadi MB, Iyiola OS, Salawu SO. Optimal control of the coronavirus pandemic with both pharmaceutical and non-pharmaceutical interventions. Int J Dyn Control 2023;:1-25. [PMID: 36743263 DOI: 10.1007/s40435-022-01112-2] [Reference Citation Analysis]
7 Chen Z, Li J, Zheng J, Jin Y, Zhang Y, Tang F, Li J, Cheng H, Jiang L, Wen H, Hong C, Zeng X, Huang S, Lu B, Li L, Wang Z. Emerging Omicron subvariants evade neutralizing immunity elicited by vaccine or BA.1/BA.2 infection. J Med Virol 2023;95:e28539. [PMID: 36719034 DOI: 10.1002/jmv.28539] [Reference Citation Analysis]
8 Li S, Wu J, Jiang W, He H, Zhou Y, Wu W, Gao Y, Xie M, Xia A, He J, Zhang Q, Han Y, Wang N, Zhu G, Wang Q, Zhang Z, Mayer CT, Wang K, Wang X, Wang J, Chen Z, Jiang S, Sun L, Xia R, Wang Q. Characterization of cross-reactive monoclonal antibodies against SARS-CoV-1 and SARS-CoV-2: Implication for rational design and development of pan-sarbecovirus vaccines and neutralizing antibodies. J Med Virol 2023;95:e28440. [PMID: 36573441 DOI: 10.1002/jmv.28440] [Reference Citation Analysis]
9 Veneziano C, Marascio N, De Marco C, Quaresima B, Biamonte F, Trecarichi EM, Santamaria G, Quirino A, Torella D, Quattrone A, Matera G, Torti C, De Filippo C, Costanzo FS, Viglietto G. The Spread of SARS-CoV-2 Omicron Variant in CALABRIA: A Spatio-Temporal Report of Viral Genome Evolution. Viruses 2023;15. [PMID: 36851622 DOI: 10.3390/v15020408] [Reference Citation Analysis]
10 Sirison K, Nittayasoot N, Techasuwanna R, Cetthakrikul N, Suphanchaimat R. Cost-Effectiveness Analysis of COVID-19 Vaccine Booster Dose in the Thai Setting during the Period of Omicron Variant Predominance. Trop Med Infect Dis 2023;8. [PMID: 36828507 DOI: 10.3390/tropicalmed8020091] [Reference Citation Analysis]
11 Zhang F, Sun R, Qu C, Ma X, Zhang C. Cold chain-affiliated associated SARS-CoV-2 omicron BA.2 infections, Qingdao, Shandong, China, 2022. Arch Med Sci 2023;19:288-91. [PMID: 36817683 DOI: 10.5114/aoms/155882] [Reference Citation Analysis]
12 Wangchuk T, Kinga, Wangdi U, Tshering U, Wangdi K. Hand Hygiene, Face Mask Use, and Associated Factors during the COVID-19 Pandemic among the Students of Mongar Higher Secondary School, Bhutan: A Cross-Sectional Study. Int J Environ Res Public Health 2023;20. [PMID: 36673813 DOI: 10.3390/ijerph20021058] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Meng W, Guo S, Cao S, Shuda M, Robinson-McCarthy LR, McCarthy KR, Shuda Y, Paniz Mondolfi AE, Bryce C, Grimes Z, Sordillo EM, Cordon-Cardo C, Li P, Zhang H, Perlman S, Guo H, Gao SJ, Chang Y, Moore PS. Development and characterization of a new monoclonal antibody against SARS-CoV-2 NSP12 (RdRp). J Med Virol 2023;95:e28246. [PMID: 36271490 DOI: 10.1002/jmv.28246] [Reference Citation Analysis]
14 Dhama K, Nainu F, Frediansyah A, Yatoo MI, Mohapatra RK, Chakraborty S, Zhou H, Islam MR, Mamada SS, Kusuma HI, Rabaan AA, Alhumaid S, Mutair AA, Iqhrammullah M, Al-Tawfiq JA, Mohaini MA, Alsalman AJ, Tuli HS, Chakraborty C, Harapan H. Global emerging Omicron variant of SARS-CoV-2: Impacts, challenges and strategies. J Infect Public Health 2023;16:4-14. [PMID: 36446204 DOI: 10.1016/j.jiph.2022.11.024] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
15 Djordjevic M, Markovic S, Salom I, Djordjevic M. Understanding risk factors of a new variant outburst through global analysis of Omicron transmissibility. Environ Res 2023;216:114446. [PMID: 36208783 DOI: 10.1016/j.envres.2022.114446] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Zhang GF, Meng W, Chen L, Ding L, Sun S, Wang X, Huang Y, Guo H, Gao SJ. Infectivity of pseudotyped SARS-CoV-2 variants of concern in different human cell types and inhibitory effects of recombinant spike protein and entry-related cellular factors. J Med Virol 2023;95:e28437. [PMID: 36573430 DOI: 10.1002/jmv.28437] [Reference Citation Analysis]
17 Elssaig EH, Alnour TMS, Ullah MF, Ahmed-Abakur EH. Omicron SARS-CoV-2 Variants in an In Silico Genomic Comparison Study with the Original Wuhan Strain and WHO-Recognized Variants of Concern. Pol J Microbiol 2022;71:577-87. [PMID: 36537060 DOI: 10.33073/pjm-2022-053] [Reference Citation Analysis]
18 Junxiang Wang, Kaiyi Li, Xinyue Mei, Jinpeng Cao, Jiaying Zhong, Peiyu Huang, Qi Luo, Guichang Li, Rui Wei, Nanshan Zhong, Zhuxiang Zhao, Zhongfang Wang. SARS-CoV-2 vaccination-infection pattern imprints and diversifies T cell differentiation and neutralizing response against Omicron subvariants. Cell Discov 2022;8:136. [PMID: 36543767 DOI: 10.1038/s41421-022-00501-3] [Reference Citation Analysis]
19 Eckermann S. Globally optimal trial design and risk sharing arrangements are key to avoiding opportunity costs of delay and enabling equitable, feasible and effective global vaccine research and implementation in current or future pandemics. Front Public Health 2022;10:1085319. [PMID: 36582386 DOI: 10.3389/fpubh.2022.1085319] [Reference Citation Analysis]
20 Li J, Li X, Wang E, Yang J, Li J, Huang C, Zhang Y, Chen K. Neutralizing Antibodies against the SARS-CoV-2 Delta and Omicron BA.1 following Homologous CoronaVac Booster Vaccination. Vaccines (Basel) 2022;10. [PMID: 36560521 DOI: 10.3390/vaccines10122111] [Reference Citation Analysis]
21 Makulo J, Mbala P, Nlandu Y, Kabwe B, Wumba R, Aziza AA, Mandina MN, Mangala D, Bepouka BI, Odio JO, Longokolo M, Mukenge EK, Kamwiziku G, Kingand EL, Bashengezi C, Kabanda G, Longo-mbenza B. SARS-CoV2 mutations and impact on mortality: observational study in a sub- Saharan Africa hospital.. [DOI: 10.21203/rs.3.rs-2343765/v1] [Reference Citation Analysis]
22 Pavan M, Bassani D, Sturlese M, Moro S. From the Wuhan-Hu-1 strain to the XD and XE variants: is targeting the SARS-CoV-2 spike protein still a pharmaceutically relevant option against COVID-19? J Enzyme Inhib Med Chem 2022;37:1704-14. [PMID: 35695095 DOI: 10.1080/14756366.2022.2081847] [Reference Citation Analysis]
23 Roohani J, Keikha M. Global challenge with the SARS-CoV-2 omicron BA.2 (B.1.1.529.2) subvariant: Should we be concerned? World J Virol 2022; 11(6): 496-501 [DOI: 10.5501/wjv.v11.i6.496] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Zaib S, Akram F, Liaqat ST, Altaf MZ, Khan I, Dera AA, Uddin J, Khan A, Al-Harrasi A. Bioinformatics approach for the construction of multiple epitope vaccine against omicron variant of SARS-CoV-2. Sci Rep 2022;12:19087. [PMID: 36352060 DOI: 10.1038/s41598-022-23550-w] [Reference Citation Analysis]
25 Chauhan D, Chakravarty N, Jeyachandran AV, Jayakarunakaran A, Sinha S, Mishra R, Arumugaswami V, Ramaiah A. In Silico Genome Analysis Reveals the Evolution and Potential Impact of SARS-CoV-2 Omicron Structural Changes on Host Immune Evasion and Antiviral Therapeutics. Viruses 2022;14. [PMID: 36366559 DOI: 10.3390/v14112461] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Spirito F, Caponio VC, Mazzoccoli G, Lo Muzio L. Monoclonal antibodies and oral pills for COVID-19: new possibilities for solid organ transplanted patients? Chirurgia 2022;35. [DOI: 10.23736/s0394-9508.22.05495-x] [Reference Citation Analysis]
27 Kurskaya OG, Sharshov KA, Solomatina MV, Voevoda MI, Shestopalov AM, Meerovich GA, Strakhovskaya MG. Photodynamic inactivation of SARS-CoV-2 on inanimate surfaces. Laser Phys Lett 2022;19:115601. [DOI: 10.1088/1612-202x/ac9598] [Reference Citation Analysis]
28 Xu X, Zhou S, Chen C, Li J, Wu H, Jin G, Zhou J, Wang G, Cao M, Sun D, Zhang W, Peng W, Pu Y, Sun Y, Fang B, Xu J. Efficacy and safety of Reyanning mixture in patients infected with SARS-CoV-2 Omicron variant: A prospective, open-label, randomized controlled trial. Phytomedicine 2023;108:154514. [DOI: 10.1016/j.phymed.2022.154514] [Reference Citation Analysis]
29 Kaur L, Ahirwar AK. Omicron variant of SARS-CoV-2: a review of existing literature. Horm Mol Biol Clin Investig 2022. [PMID: 36257917 DOI: 10.1515/hmbci-2022-0023] [Reference Citation Analysis]
30 Mannsverk S, Bergholm J, Palanisamy N, Ellström P, Kaden R, Lindh J, Lennerstrand J. SARS-CoV-2 variants of concern and spike protein mutational dynamics in a Swedish cohort during 2021, studied by Nanopore sequencing. Virol J 2022;19:164. [PMID: 36258215 DOI: 10.1186/s12985-022-01896-x] [Reference Citation Analysis]
31 Pipitò L, Reynolds CA, Deganutti G. Is the Stalk of the SARS-CoV-2 Spike Protein Druggable?. [DOI: 10.1101/2022.10.06.511069] [Reference Citation Analysis]
32 Selvavinayagam ST, Yong YK, Joseph N, Hemashree K, Tan HY, Zhang Y, Rajeshkumar M, Kumaresan A, Kalpana R, Kalaivani V, Monika AVD, Suvaithenamudhan S, Kannan M, Murugesan A, Narayanasamy K, Palani S, Larsson M, Shankar EM, Raju S. Low SARS-CoV-2 viral load among vaccinated individuals infected with Delta B.1.617.2 and Omicron BA.1.1.529 but not with Omicron BA.1.1 and BA.2 variants. Front Public Health 2022;10:1018399. [PMID: 36211690 DOI: 10.3389/fpubh.2022.1018399] [Reference Citation Analysis]
33 Rana R, Kant R, Huirem RS, Bohra D, Ganguly NK. Omicron variant: Current insights and future directions. Microbiol Res 2022;265:127204. [PMID: 36152612 DOI: 10.1016/j.micres.2022.127204] [Reference Citation Analysis]
34 Liang HY, Wu Y, Yau V, Yin HX, Lowe S, Bentley R, Ahmed MA, Zhao W, Sun C. SARS-CoV-2 Variants, Current Vaccines and Therapeutic Implications for COVID-19. Vaccines (Basel) 2022;10:1538. [PMID: 36146616 DOI: 10.3390/vaccines10091538] [Reference Citation Analysis]
35 Khemiri H, Ayouni K, Triki H, Haddad-Boubaker S. SARS-CoV-2 infection in pediatric population before and during the Delta (B.1.617.2) and Omicron (B.1.1.529) variants era. Virol J 2022;19:144. [PMID: 36076271 DOI: 10.1186/s12985-022-01873-4] [Reference Citation Analysis]
36 Najafi-fard S, Petruccioli E, Farroni C, Petrone L, Vanini V, Cuzzi G, Salmi A, Altera AMG, Navarra A, Alonzi T, Nicastri E, Palmieri F, Gualano G, Carlini V, Noonan DM, Albini A, Goletti D. Evaluation of the immunomodulatory effects of interleukin-10 on peripheral blood immune cells of COVID-19 patients: Implication for COVID-19 therapy. Front Immunol 2022;13:984098. [DOI: 10.3389/fimmu.2022.984098] [Reference Citation Analysis]
37 Dhawan M, Saied AA, Mitra S, Alhumaydhi FA, Emran TB, Wilairatana P. Omicron variant (B.1.1.529) and its sublineages: What do we know so far amid the emergence of recombinant variants of SARS-CoV-2? Biomed Pharmacother 2022;154:113522. [PMID: 36030585 DOI: 10.1016/j.biopha.2022.113522] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
38 Ouyang J, Zaongo SD, Harypursat V, Li X, Routy JP, Chen Y. SARS-CoV-2 pre-exposure prophylaxis: A potential COVID-19 preventive strategy for high-risk populations, including healthcare workers, immunodeficient individuals, and poor vaccine responders. Front Public Health 2022;10:945448. [PMID: 36003629 DOI: 10.3389/fpubh.2022.945448] [Reference Citation Analysis]
39 Chakraborty C, Bhattacharya M, Sharma AR, Mallik B. Omicron (B.1.1.529) - A new heavily mutated variant: Mapped location and probable properties of its mutations with an emphasis on S-glycoprotein. Int J Biol Macromol 2022;219:980-97. [PMID: 35952818 DOI: 10.1016/j.ijbiomac.2022.07.254] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
40 Hayek S, Ben-Shlomo Y, Dagan N, Reis BY, Barda N, Kepten E, Roitman A, Shapira S, Yaron S, Balicer RD, Netzer D, Peretz A. Effectiveness of REGEN-COV antibody combination in preventing severe COVID-19 outcomes. Nat Commun 2022;13:4480. [PMID: 35918340 DOI: 10.1038/s41467-022-32253-9] [Reference Citation Analysis]
41 Yang Y. How the emergence of the omicron variant may change people’s attitudes toward the COVID-19 pandemic. Front Psychol 2022;13:922470. [DOI: 10.3389/fpsyg.2022.922470] [Reference Citation Analysis]
42 Zhang Y, Tan W, Lou Z, Zhao Y, Zhang J, Liang H, Li N, Zhu X, Ding L, Huang B, Zhou W, Guo Y, Yang Z, Qiao Y, He Z, Ma B, He Y, Zhu D, Wang Z, Chang Z, Zhao X, Wang W, Xu Y, Zhu H, Zheng X, Wang C, Xu G, Wu G, Wang H, Yang X. Vaccination with Omicron Inactivated Vaccine in Pre-vaccinated Mice Protects against SARS-CoV-2 Prototype and Omicron Variants. Vaccines 2022;10:1149. [DOI: 10.3390/vaccines10071149] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
43 Pipitò L, Rujan RM, Reynolds CA, Deganutti G. Molecular dynamics studies reveal structural and functional features of the SARS-CoV-2 spike protein. Bioessays 2022;:e2200060. [PMID: 35843871 DOI: 10.1002/bies.202200060] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
44 Forgham H, Kakinen A, Qiao R, Davis TP. Keeping up with the COVID's—Could siRNA‐based antivirals be a part of the answer? Exploration 2022. [DOI: 10.1002/exp.20220012] [Reference Citation Analysis]
45 Zhang Y, Zhang G, Ling J. Medicinal Fungi with Antiviral Effect. Molecules 2022;27:4457. [DOI: 10.3390/molecules27144457] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
46 Mengist HM, Kombe Kombe JA, Jin T. Immune Evasion by the Highly Mutated SARS-CoV-2 Omicron Variant. IDR 2022;Volume 15:4013-27. [DOI: 10.2147/idr.s366437] [Reference Citation Analysis]
47 Kandeel M, El-Deeb W. Omicron variant receptor-binding domain phylogenetics and molecular dynamics. Comput Biol Med 2022;146:105633. [PMID: 35605487 DOI: 10.1016/j.compbiomed.2022.105633] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
48 Nguyen HL, Thai NQ, Nguyen PH, Li MS. SARS-CoV-2 Omicron Variant Binds to Human Cells More Strongly than the Wild Type: Evidence from Molecular Dynamics Simulation. J Phys Chem B 2022;126:4669-78. [PMID: 35723978 DOI: 10.1021/acs.jpcb.2c01048] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
49 Ortega MA, García-montero C, Fraile-martinez O, Colet P, Baizhaxynova A, Mukhtarova K, Alvarez-mon M, Kanatova K, Asúnsolo A, Sarría-santamera A. Recapping the Features of SARS-CoV-2 and Its Main Variants: Status and Future Paths. JPM 2022;12:995. [DOI: 10.3390/jpm12060995] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
50 Chen R, Jiang Q. Evolution of telemedicine in China during COVID-19 pandemic: from 2020 to 2022. J Public Health Pol. [DOI: 10.1057/s41271-022-00353-x] [Reference Citation Analysis]
51 Khandia R, Singhal S, Alqahtani T, Kamal MA, El-Shall NA, Nainu F, Desingu PA, Dhama K. Emergence of SARS-CoV-2 Omicron (B.1.1.529) variant, salient features, high global health concerns and strategies to counter it amid ongoing COVID-19 pandemic. Environ Res 2022;209:112816. [PMID: 35093310 DOI: 10.1016/j.envres.2022.112816] [Cited by in Crossref: 106] [Cited by in F6Publishing: 105] [Article Influence: 106.0] [Reference Citation Analysis]
52 Chen T, Hsu M, Lee M, Chou C. Gastrointestinal Involvement in SARS-CoV-2 Infection. Viruses 2022;14:1188. [DOI: 10.3390/v14061188] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 17.0] [Reference Citation Analysis]
53 Chugh A, Khurana N, Verma K, Sehgal I, Rolta R, Vats P, Phartyal R, Salaria D, Kaushik N, Choi EH, Verma M, Kaushik NK. Changing Dynamics of SARS-CoV-2: A Global Challenge. Applied Sciences 2022;12:5546. [DOI: 10.3390/app12115546] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
54 Shinoda H, Iida T, Makino A, Yoshimura M, Ishikawa J, Ando J, Murai K, Sugiyama K, Muramoto Y, Nakano M, Kiga K, Cui L, Nureki O, Takeuchi H, Noda T, Nishimasu H, Watanabe R. Automated amplification-free digital RNA detection platform for rapid and sensitive SARS-CoV-2 diagnosis. Commun Biol 2022;5:473. [PMID: 35614128 DOI: 10.1038/s42003-022-03433-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
55 Lindahl H, Klingström J, Da Silva Rodrigues R, Christ W, Chen P, Ljunggren HG, Buggert M, Aleman S, Smith CIE, Bergman P. Neutralizing SARS-CoV-2 Antibodies in Commercial Immunoglobulin Products Give Patients with X-Linked Agammaglobulinemia Limited Passive Immunity to the Omicron Variant. J Clin Immunol 2022. [PMID: 35538387 DOI: 10.1007/s10875-022-01283-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
56 Phan T, Boes S, McCullough M, Gribschaw J, Marsh JW, Harrison LH, Wells A. First detection of SARS-CoV-2 Omicron BA.4 variant in Western Pennsylvania, United States. J Med Virol 2022. [PMID: 35534788 DOI: 10.1002/jmv.27846] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
57 Lhendup K, Tsheten T, Rinzin T, Wangdi K. Risk Factors of Symptomatic COVID-19 in Samtse District, Bhutan. Front Public Health 2022;10:857084. [DOI: 10.3389/fpubh.2022.857084] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Mahalingam K, Surbhi, Balaji A, Ganesh R, Daniel RA, Aggarwal R, Soni KD, Singh AK, Khanna P, Gupta V, Trikha A. Is it a challenging task to work with personal protective equipment in a COVID-19 ICU: Findings from a hospital-based cross-sectional study from north India. J Family Med Prim Care 2022;11:1935-42. [PMID: 35800524 DOI: 10.4103/jfmpc.jfmpc_1937_21] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Rahmani S, Rezaei N. SARS‐CoV‐2 Omicron variant: Why global communities should take it seriously? Immunity Inflam & Disease 2022;10. [DOI: 10.1002/iid3.618] [Reference Citation Analysis]
60 Varret M, Martin FX, Varret F, Lévy J. A tentative tracking of the SARS-Cov2 pandemic in France, based on a corrected SIR model including vaccination effects. EPJ Web Conf 2022;263:01002. [DOI: 10.1051/epjconf/202226301002] [Reference Citation Analysis]
61 Ribeiro Xavier C, Sachetto Oliveira R, da Fonseca Vieira V, Lobosco M, Weber dos Santos R. Characterisation of Omicron Variant during COVID-19 Pandemic and the Impact of Vaccination, Transmission Rate, Mortality, and Reinfection in South Africa, Germany, and Brazil. BioTech 2022;11:12. [DOI: 10.3390/biotech11020012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
62 Liu S, Kang M, Zhao N, Zhuang Y, Li S, Song T. Comprehensive narrative review of real-world COVID-19 vaccines: viewpoints and opportunities. Medical Review 2022;2:169-196. [DOI: 10.1515/mr-2021-0021] [Reference Citation Analysis]
63 Basheer M, Saad E, Assy N. The Cytokine Storm in COVID-19: The Strongest Link to Morbidity and Mortality in the Current Epidemic. COVID 2022;2:540-52. [DOI: 10.3390/covid2050040] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
64 El Mazouri S, Bendani H, Boumajdi N, Chaoui Roqai M, Aanniz T, Seffar M, Kabbaj H, El Amin G, Zouaki A, Amzazi S, Ouadghiri M, Belyamani L, Ibrahimi A. Report of SARS-CoV-2 BA.1 Lineage in Morocco. Microbiol Resour Announc 2022;:e0016922. [PMID: 35416694 DOI: 10.1128/mra.00169-22] [Reference Citation Analysis]
65 Li Z, Zhang JZH. Mutational Effect of Some Major COVID-19 Variants on Binding of the S Protein to ACE2. Biomolecules 2022;12:572. [DOI: 10.3390/biom12040572] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
66 Bahadur Gurung A, Ajmal Ali M, Elshikh MS, Aref I, Amina M, Lee J. An in silico approach unveils the potential of antiviral compounds in preclinical and clinical trials as SARS-CoV-2 Omicron inhibitors. Saudi Journal of Biological Sciences 2022. [DOI: 10.1016/j.sjbs.2022.103297] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
67 Chitty SA, Mobbs S, Rifkin BS, Stogner SW, Lewis MS, Betancourt J, DellaVolpe J, Abouzahr F, Wilhelm AM, Szerlip HM, Parikh A, Gaeta RM, Rivera I, Park C, Levi B, Anesi GL, Alcover KC, Arnold TB, Howard JT, Sharma K, Pratt KP, Stewart IJ, Chung KK. A Multicenter Evaluation of the Seraph 100 Microbind Affinity Blood Filter for the Treatment of Severe COVID-19. Crit Care Explor 2022;4:e0662. [PMID: 35506015 DOI: 10.1097/CCE.0000000000000662] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
68 Bader SM, Cooney JP, Pellegrini M, Doerflinger M. Programmed cell death: the pathways to severe COVID-19? Biochem J 2022;479:609-28. [PMID: 35244141 DOI: 10.1042/BCJ20210602] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
69 Nörz D, Grunwald M, Tang HT, Weinschenk C, Günther T, Robitaille A, Giersch K, Fischer N, Grundhoff A, Aepfelbacher M, Pfefferle S, Lütgehetmann M. Clinical Evaluation of a Fully-Automated High-Throughput Multiplex Screening-Assay to Detect and Differentiate the SARS-CoV-2 B.1.1.529 (Omicron) and B.1.617.2 (Delta) Lineage Variants. Viruses 2022;14:608. [DOI: 10.3390/v14030608] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
70 Omotuyi O, Olubiyi O, Nash O, Afolabi E, Oyinloye B, Fatumo S, Femi-oyewo M, Bogoro S. SARS-CoV-2 Omicron spike glycoprotein receptor binding domain exhibits super-binder ability with ACE2 but not convalescent monoclonal antibody. Computers in Biology and Medicine 2022;142:105226. [DOI: 10.1016/j.compbiomed.2022.105226] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 20.0] [Reference Citation Analysis]
71 Schiuma G, Beltrami S, Bortolotti D, Rizzo S, Rizzo R. Innate Immune Response in SARS-CoV-2 Infection. Microorganisms 2022;10:501. [DOI: 10.3390/microorganisms10030501] [Reference Citation Analysis]
72 Zheng J, Wang Z, Li J, Zhang Y, Jiang L, Fu Y, Jin Y, Cheng H, Li J, Chen Z, Tang F, Lu B, Li L, Zhang X. High amounts of SARS-CoV-2 in aerosols exhaled by patients with Omicron variant infection. J Infect 2022:S0163-4453(22)00075-5. [PMID: 35183607 DOI: 10.1016/j.jinf.2022.02.015] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
73 Hussein M, Andrade dos Ramos Z, Berkhout B, Herrera-carrillo E. In Silico Prediction and Selection of Target Sequences in the SARS-CoV-2 RNA Genome for an Antiviral Attack. Viruses 2022;14:385. [DOI: 10.3390/v14020385] [Reference Citation Analysis]
74 da Silva Torres MK, Bichara CDA, de Almeida MDNDS, Vallinoto MC, Queiroz MAF, Vallinoto IMVC, dos Santos EJM, de Carvalho CAM, Vallinoto ACR. The Complexity of SARS-CoV-2 Infection and the COVID-19 Pandemic. Front Microbiol 2022;13:789882. [DOI: 10.3389/fmicb.2022.789882] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
75 Silva SJRD, Lima SCD, Silva RCD, Kohl A, Pena L. Viral Load in COVID-19 Patients: Implications for Prognosis and Vaccine Efficacy in the Context of Emerging SARS-CoV-2 Variants. Front Med 2022;8:836826. [DOI: 10.3389/fmed.2021.836826] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
76 Mendiola-pastrana IR, López-ortiz E, Río de la Loza-zamora JG, González J, Gómez-garcía A, López-ortiz G. SARS-CoV-2 Variants and Clinical Outcomes: A Systematic Review. Life 2022;12:170. [DOI: 10.3390/life12020170] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
77 Mills MG, Hajian P, Bakhash SM, Xie H, Mantzke D, Zhu H, Perchetti GA, Huang M, Pepper G, Jerome KR, Roychoudhury P, Greninger AL. Rapid and Accurate Identification of SARS-CoV-2 Omicron Variants Using Droplet Digital PCR (RT-ddPCR).. [DOI: 10.1101/2022.01.11.22268981] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
78 Li J, Du P, Yang L, Zhang J, Song C, Chen D, Song Y, Ding N, Hua M, Han K, Song R, Xie W, Chen Z, Wang X, Liu J, Xu Y, Gao G, Wang Q, Pu L, Di L, Li J, Yue J, Han J, Zhao X, Yan Y, Yu F, Wu AR, Zhang F, Gao YQ, Huang Y, Wang J, Zeng H, Chen C. Two-step fitness selection for intra-host variations in SARS-CoV-2. Cell Rep 2022;38:110205. [PMID: 34982968 DOI: 10.1016/j.celrep.2021.110205] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 14.0] [Reference Citation Analysis]
79 Estrela PFN, dos Santos CA, Resende PC, Lima PM, da Silva TDSC, Saboia-vahia L, Siqueira MM, Silveira-lacerda EDP, Duarte GRM. Fast, low-cost and highly specific colorimetric RT-LAMP assays for inference of SARS-CoV-2 Omicron BA.1 and BA.2 lineages. Analyst 2022. [DOI: 10.1039/d2an01625g] [Reference Citation Analysis]
80 Orellana-centeno JE, Guerrero Sotelo RN. La variante SARS-CoV-2 ómicron. Revista de la Asociación Dental Mexicana 2022;79:28-31. [DOI: 10.35366/103815] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
81 Keita I, Dabo G, Doumbia L, Diarra Y, Traoré I, Traoré M, Sangaré L, Toloba Y, Diallo MA, Sy D, Gutierrez AH, Sissako A, Guindo I, Diallo M, Iknane AA, De Groot AS, Koita OA. Mutations in Spike Gene of SARS-CoV-2 that Are Associated with a Higher Viral Load: A Clinical Case Study. CRCM 2022;11:474-486. [DOI: 10.4236/crcm.2022.1111065] [Reference Citation Analysis]
82 Haruta M, Otsubo S, Otsubo Y. Characteristics of the 6th Japanese wave of COVID-19 in hemodialysis patients. Ren Replace Ther 2022;8:61. [DOI: 10.1186/s41100-022-00451-2] [Reference Citation Analysis]
83 Nasiri K, Dimitrova A. Omicron variant in the current SARS-CoV-2 pandemic. Journal of Dental Sciences 2022. [DOI: 10.1016/j.jds.2022.01.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
84 Dhawan M, Priyanka, Choudhary OP. Omicron SARS-CoV-2 variant: Reasons of emergence and lessons learnt. Int J Surg 2022;97:106198. [PMID: 34958967 DOI: 10.1016/j.ijsu.2021.106198] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 27.0] [Reference Citation Analysis]
85 Rahmani S, Rezaei N. SARS-CoV-2 Omicron (B.1.1.529) Variant: No Time to Wait! Acta Biomed 2022;93:e2022097. [PMID: 35546004 DOI: 10.23750/abm.v93i2.12712] [Reference Citation Analysis]
86 Cherne MD, Gentry AB, Nemudraia A, Nemudryi A, Hedges JF, Walk H, Blackwell K, Snyder DT, Jerome M, Madden W, Hashimi M, Sebrell TA, King DB, Plowright RK, Jutila MA, Wiedenheft B, Bimczok D. Severe Acute Respiratory Syndrome Coronavirus 2 Is Detected in the Gastrointestinal Tract of Asymptomatic Endoscopy Patients but Is Unlikely to Pose a Significant Risk to Healthcare Personnel. Gastro Hep Adv 2022;1:844-52. [PMID: 35765598 DOI: 10.1016/j.gastha.2022.06.002] [Reference Citation Analysis]
87 Dhawan M, Priyanka, Sahni A, Choudhary OP. Vaccine inequity and hesitancy: Dual factors in the emergence of novel SARS-CoV-2 variants. Ann Med Surg (Lond) 2022;73:103186. [PMID: 34961829 DOI: 10.1016/j.amsu.2021.103186] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
88 Islam MR, Hossain MJ. Detection of SARS-CoV-2 Omicron (B.1.1.529) variant has created panic among the people across the world: What should we do right now? J Med Virol 2021. [PMID: 34939691 DOI: 10.1002/jmv.27546] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 14.0] [Reference Citation Analysis]
89 Lundberg A, Lorenzo Redondo R, Ozer EA, Hawkins C, Hultquist JF, Welch S, Prasad PV, Oehmke J, Achenbach CJ, Murphy RL, White J, Havey R, Post LA. Has Omicron Changed the Evolution of the Pandemic? (Preprint). JMIR Public Health and Surveillance. [DOI: 10.2196/35763] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
90 Wang Z, Yang L. In the age of Omicron variant: Paxlovid raises new hopes of COVID-19 recovery. J Med Virol 2021. [PMID: 34936106 DOI: 10.1002/jmv.27540] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 12.0] [Reference Citation Analysis]
91 Lundberg AL, Lorenzo-redondo R, Ozer EA, Hawkins CA, Hultquist JF, Welch SB, Prasad PV, Oehmke JF, Achenbach CJ, Murphy RL, White JI, Havey RJ, Post LA. Has Omicron Changed the Evolution of the Pandemic? (Preprint).. [DOI: 10.2196/preprints.35763] [Reference Citation Analysis]
92 Kannan SR, Spratt AN, Sharma K, Chand HS, Byrareddy SN, Singh K. Omicron SARS-CoV-2 variant: Unique features and their impact on pre-existing antibodies. J Autoimmun 2022;126:102779. [PMID: 34915422 DOI: 10.1016/j.jaut.2021.102779] [Cited by in Crossref: 89] [Cited by in F6Publishing: 99] [Article Influence: 44.5] [Reference Citation Analysis]
93 Kandeel M, Mohamed MEM, Abd El-Lateef HM, Venugopala KN, El-Beltagi HS. Omicron variant genome evolution and phylogenetics. J Med Virol 2021. [PMID: 34888894 DOI: 10.1002/jmv.27515] [Cited by in Crossref: 59] [Cited by in F6Publishing: 68] [Article Influence: 29.5] [Reference Citation Analysis]
94 Omotuyi IO, Olubiyi O, Nash O, Afolabi E, Oyinloye B, Fatumo S, Femi-oyewo MN, Bogoro S. SARS-CoV-2 Omicron Spike Glycoprotein Receptor Binding Domain Exhibits Super-Binder Ability with ACE2 but not Convalescent Monoclonal Antibody.. [DOI: 10.1101/2021.12.09.471885] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
95 Battaglia R, Alonzo R, Pennisi C, Caponnetto A, Ferrara C, Stella M, Barbagallo C, Barbagallo D, Ragusa M, Purrello M, Di Pietro C. MicroRNA-Mediated Regulation of the Virus Cycle and Pathogenesis in the SARS-CoV-2 Disease. Int J Mol Sci 2021;22:13192. [PMID: 34947989 DOI: 10.3390/ijms222413192] [Cited by in F6Publishing: 3] [Reference Citation Analysis]